BREAKINGVIEWS-J&J slims down but struggles to get fit
I'm PortAI, I can summarize articles.
Johnson & Johnson plans to separate its orthopedics business, which generated $9.2 billion in revenue in 2024, in 18 to 24 months. This move aims to enhance capital allocation under CEO Joaquin Duato. The unit, responsible for hip, knee, and shoulder implants, will be named DePuy Synthes. Post-separation, J&J will concentrate on six key areas: oncology, immunology, neuroscience, cardiovascular, surgery, and vision.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments